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Association between silent Atrial Fibrillation and heart failure after
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Atrial Fibrillation (AF) complicating an acute myocardial infarction (AMI)
is frequent and associated with a worse prognosis after MI, particularly
because of lethal heart failure (HF) episodes and cardiogenic shock. Although
silent AF has also been suggested to be common in AMI, its association with
development of heart failure during the first days after AMI remains unknown.
In this study we aimed to assess a potential association between silent AF and
episodes of heart failure after AMI.
Methods: For AF screening, 581 consecutive AMI were prospectively ana-
lyzed by Continuous ECG Scope Monitoring (CSM) for 48H after hospital
admission. Left Ventricular Ejection Fraction (LVEF) was determined on
admission by echocardiography. We analyzed the study population into
3 groups: No AF, silent AF (asymptomatic episodes of AF lasting at least
>30 sec) and symptomatic AF (symptomatic episodes of AF that lasted
≥12 hours). Diagnosis of heart failure episode was based on plasmatic level of
Nt-ProBNP.
Results: Ninety-five (16.4%) patients had AF on CSM after MI, of whom
76 (80%) developed silent AF. Compared with No AF group, patients with
silent AF were markedly older (80 (69-85) vs 62 (53-74);p<0.001), more fre-
quently women (45 vs 27%;p=0.006), hypertensive (76vs52%;p<0.001) but
less smoker (18vs38%;p<0.001). On admission, patients with silent AF had
animpaired LVEF (46%(13) vs 54%(11);p<0.001), with higher Nt-ProBNP
(1817 (556-7078) vs435 (111-1512);p<0.001) and more frequent episode of
heart failure (42 vs21%;p<0.001).Comparing the three groups, heart failure
episodes during the acute phase after myocardial infarction were more fre-
quent in silent AF group (42%) and in symptomatic AF group (53%)than in
noAF group (21%), with p<0.001.
Conclusion: This studyshows that silent AF is very common after MI
(16.4%), and highlights for the first time that itis significantly associated with
episodes of heart failure. This outcome suggests the potential impact of silent
AF on the prognosis of patients after AMI.
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Long-term follow-up after implantable cardioverter defibrillator in
patients with Brugada syndrome: a multicenter French experience
Aimé Bonny (1), Amara Walid (2), Hasnaa Salih (2), Joelci Tonet (3),
Stéphane Dennetierre (1), Guy Fontaine (3), Robert Frank (3), Françoise
Hidden-Lucet (3)
(1) CH Roubaix, Roubaix, France – (2) CH Montfermeil, Montfermeil,
France – (3) Hôpital Pitié-Salpêtrière, cardiologie, unité rythmologie,
Paris, France
Background and objective: Implantation of a cardioverter defibrillator
(ICD) is a frequently recommended treatment for symptomatic Brugada syn-
drome (BrS). However, complications related to the device have been
reported.
Methods and results: We assessed the benefit / morbidity ratio of this
mode of therapy in a cohort of 34 patients implanted in 3 French experienced
centers between January 1, 2002 and November 30, 2010. The mean age was
48±14 years, 4 (12%) female. Twenty nine (85%) patients had spontaneous
typical coved Type I ECG pattern, 15 (44%) had family history of sudden car-
diac death (SCD) and 24 (88%) had positive EP study. ICD implantation was
based on aborted sudden cardiac arrest (SCA) in 3 (9%), syncope in 19 (56%)
or high risk status (spontaneous type 1 ECG in conjunction with a family his-
tory of SCD and/or a positive EP study) in 12 (35%). The median follow-up
period was 74±23 (9-127) months. One patient with prior cardiac arrest died
of a non-cardiac cause, 5 (15%) patients had appropriate device therapy; all
with spontaneous type I ECG and previous syncope but none with prior car-
diac arrest. Overall complication rate was 26%. Six (27%) symptomatic and 3
(25%) asymptomatic patients experienced complications. Five (14%) patients
(4 with previous syncope and 1 asymptomatic) experienced inappropriate
shocks and 4 (12%) had other complications: 2 patients had lead rupture,
1 lead displacement, and 1 pneumothorax during device replacement. These
complications occurred in 2 asymptomatic and 2 symptomatic (1 syncope and
1 prior aborted SCA) patients. No case of SCD was observed in ICD carriers.
Conclusion: Appropriate device therapy after a median follow-up period
of 6 years was observed in patients with prior syncope and none in asymptom-
atic patients. Complication rate was leading not to recommend ICD implanta-
tion in asymptomatic Brugada patients and to carefully evaluate the risk /
morbidity ratio in subject with non spontaneous coved type ECG pattern.
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Background: Cardiac resynchronization therapy (CRT) prolongs survival
in appropriately selected patients with heart failure. Right ventricular (RV)
dysfunction is associated with a worse prognosis in this setting but it is not
clear whether it influences the clinical response to CRT.
Method and Results: Of 813 patients enrolled in the Cardiac Resynchro-
nization-Heart Failure (CARE-HF) study, 688 had tricuspid plane systolic
excursion (TAPSE) measured at baseline and 345 of these were assigned to
CRT. Their median (IQR) age was 66 (58-71) years, left ventricular (LV)
ejection fraction was 24 (21-28)% and TAPSE was 19 (16-22)mm. Baseline
LV function and size and QRS duration were similar amongst TAPSE tertiles
but those in the worst tertile (TAPSE<17.4 mm) had higher plasma concentra-
tions of amino-terminal pro-brain natriuretic peptide (NT-proBNP) and were
more likely to have ischaemic heart disease. In response to CRT, patients in
the lowest tertile of TAPSE had less LV reverse remodelling but greater
reductions in NT-proBNP and pulmonary artery pressure and more RV
reverse remodelling compared to other tertiles. The median (IQR) follow-up
for mortality was 748 (582-950) days during which 213 deaths occurred.
Patients with lower TAPSE had a higher mortality regardless of assigned
treatment (p<0.001). Greater inter-ventricular mechanical delay, New York
Heart Association class, mitral regurgitation and NT-proBNP, lower TAPSE
and assignment to the control group were independently associated with
higher mortality. Reduction in mortality with CRT was similar in each tertile.
Conclusion: RV dysfunction is a powerful determinant of prognosis
amongst candidates for CRT, regardless of treatment assigned: CRT improved
prognostic in patients with RV dysfunction despite less improvement in LV
remodelling.
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Background: Cardiac resynchronization Therapy (CRT) improves left
ventricular ejection fraction (LVEF) in patients with congestive heart failure,
LV systolic dysfunction and a wide QRS complex. Previous reports suggest
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